Lineage's Lead Candidate Used To Treat Patient With Retinal Disease Under Compassionate Use

Under a named patient compassionate use approval by the Israeli Ministry of Health, Lineage Cell Therapeutics Inc's LCTX OpRegen has been used to treat a patient suffering from adult-onset vitelliform macular dystrophy (AVMD) at Hadassah-Hebrew University Medical Center in Jerusalem.
The patient was presented with sudden and severe visual acuity decreases in one eye. BCVA in the worse vision eye was measured at 20/200, compared to 20/40 in the patient's contralateral eye.
The delivery of OpRegen retinal pigment epithelium (RPE) cells via pars plana vitrectomy was successful, with no complications arising during the procedure, and the patient remains in follow-up.
AVMD is a retinal disease characterized by round, yellowish deposits found beneath the central retina or macula responsible for sharp central vision. It causes progressive vision loss and usually begins after age 40.
OpRegen is an investigational cell therapy consisting of allogeneic RPE cells administered to the subretinal space.
It is currently being investigated in a 24-patient Phase 1/2a trial to treat dry age-related macular degeneration (AMD) with geographic atrophy (GA).
Price Action: LCTX shares are trading 6.2% lower at $2.22 on the last check Monday.